Cancer genomic medicine in Japan and the roles of pharmacists

Tohru Aomori, Hiroomi Sakurai, Hiroshi Nishihara

研究成果: Review article査読

抄録

Cancer genomic medicine (CGM) is a medical service that provides optimized treatment for each patient based on genes, biomarkers, environment, and lifestyle. In Japan, the approval of designed core hospitals for CGM started in 2017. In June 2019, two types of cancer gene panel tests became available in the national health insurance system, and CGM was socially implemented. While CGM is still in its infancy and there are some issues that need to be resolved, there are cases where the treatment has shown dramatic results. The present review highlights the CGM system in Japan, the issues it faces, and the role of pharmacists in this system.

本文言語English
ページ(範囲)242-245
ページ数4
ジャーナルPharmacogenetics and Genomics
32
6
DOI
出版ステータスPublished - 2022 8月 1

ASJC Scopus subject areas

  • 分子医療
  • 分子生物学
  • 遺伝学
  • 薬理学、毒性学および薬学(全般)
  • 遺伝学(臨床)

フィンガープリント

「Cancer genomic medicine in Japan and the roles of pharmacists」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル